Ro

Introducing Ro’s GLP-1 Supply Tracker – a free, open access tool to help patients and providers find out which medications are available (and where) and which aren’t. https://lnkd.in/en5qTGAa We built this tracker to give patients an easier way to navigate GLP-1 shortages, by: 1️⃣ Clearly showing which GLP-1s are currently in shortage by drug and dose 2️⃣ Making it easy for everyone to crowdsource where and when they find GLP-1 supply or, when they cannot, to submit a shortage report to the FDA 3️⃣ Letting anyone join our “Supply List” that sends real-time alerts when GLP-1 supply is located at a pharmacy near them 4️⃣ Sending automated notifications to patients and providers who sign-up letting them know when a drug’s status changes on the FDA’s list. Our hope is that this tracker will help ease the burden that drug shortages have placed on patients and providers, and increase access to these life-changing treatments.

What’s going on with the GLP-1 drug shortages? Since introducing our GLP-1 Supply Tracker three months ago, we've received over 60,000 drug shortage reports from patients nationwide. What does this data reveal? GLP-1s indicated for weight loss make up the vast majority of shortage reports, especially the lower doses of Wegovy and Zepbound. Dive into our latest blog to read more insights, including: ➡️ First-hand challenges patients are facing filling their prescriptions; ➡️ The latest updates from pharma companies and the FDA; ➡️ How recent trends in Tracker data point to some signs of GLP-1 supply progress. Check it out here: https://lnkd.in/gDiEjBnP

Ro's GLP-1 Insurance Coverage Checker drastically simplifies the process for patients to understand what their coverage and out-of-pocket costs would be for GLP-1s. Take a look below to see everything our report delivers to each individual patient.

Patients have long advocated for greater coverage of obesity care and treatments. Can you guess how many patients have coverage for GLP-1s for weight loss? Take the poll below to share your thoughts ⤵️

"One of the biggest problems for patients when they start this [GLP-1] journey is understanding how much this medication is going to cost and am I'm covered?" Ro's CEO Zachariah Reitano joined the Fast Money team at CNBC to share what the GLP-1 Insurance Coverage Checker offers patients and why we built it. Watch their convo here: https://lnkd.in/eYAEJJda

Introducing the GLP-1 Insurance Coverage Checker – a free tool that empowers anyone to check if their insurance covers GLP-1s medications and understand their potential out of pocket costs at the beginning of their journey. https://lnkd.in/eCyK4g-r Unfortunately, the onus is on patients to figure out their insurance coverage and it comes with multiple challenges. The GLP-1 Insurance Coverage Checker dramatically simplifies the process for patients by: ✅ Saving them time with a quick, easy-to-use online tool; ✅ Delivering a detailed report about their coverage across all GLP-1 options; ✅ Pairing coverage results with drug supply status for actionable next steps. We hope that this tool helps patients with the information they need to start their health journey with GLP-1s.

"The last eight months of our marriage is better than the last about 12 years of our marriage." Body patient Danielle has lost 85lbs since joining Ro. She shares how her experience on a GLP-1 has impacted her health and helped unlock a newfound intimacy with her husband in The Wall Street Journal. Read more about her story here: https://lnkd.in/ehnvB9bK

"Contrary to worries of the past, technology is best suited not to replace providers but in many ways to empower them to the best of their abilities each and every time they care for patients." Ro's Chief Medical Officer, Melynda Barnes, MD shares how technology can unlock our ability to scale obesity care to meet the rising demand in MedCity News. Read it here: https://lnkd.in/gDrFGFgZ

Do people treated with GLP-1s lose more muscle than those who lose weight through other means? Ro’s advisor, David Allison, and Ro’ers, Raoul Manalac and Lauren Broffman, PhD, took a close look at what the evidence had to say. In short, here’s what they found: ➡️ There’s a lack of evidence that GLP-1s lead to disproportionate muscle mass loss; ➡️ There is evidence that suggests GLP-1s may lead to improved body composition, as the loss of fat mass is often 2-3x greater than loss of fat free mass; ➡️ One study reported that GLP-1s significantly improved physical function compared to placebo. Learn more in their article, and stayed tuned for future deep dives on this topic: https://lnkd.in/eFCMBimw

"For me, the gummies work before the anxiety even hits...so in a way, I’m beating my anxiety to the punch." Zachary Zane from Men's Health Magazine shares his perspective on managing ED and how Daily Rise Gummies help him overcome performance anxiety. Read the full article to learn about his experience: https://lnkd.in/d2mqAf4B